Literature DB >> 2550427

Self-induction of 1,25-dihydroxyvitamin D3 metabolism limits receptor occupancy and target tissue responsiveness.

T A Reinhardt1, R L Horst.   

Abstract

Whole cell 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) receptor (VDR) binding assays, which measure VDR in the presence of the metabolic machinery of the cell, were used in conjunction with a cytosol binding assay for VDR to determine if self-induced metabolism of 1,25-(OH)2D3 limits VDR occupancy, total VDR levels, and target cell responsiveness. Treatment of cells with 0.5 nM 1,25-(OH)2[3H]D3 for 16 h results in up-regulation of total cell VDR from 82 to 170 fmol/mg protein as measured in a cytosol binding assay. Conversely, whole cell binding assays of VDR showed a 1,25-(OH)2D3-mediated apparent down-regulation of VDR from 90 to 40 fmol/mg protein. Scatchard analysis using the cytosol binding assay demonstrated that 1,25-(OH)2D3 treatment increased total cell VDR from 93 to 154 fmol/mg protein. In contrast, Scatchard analysis with the whole cell binding assay demonstrated that 1,25-(OH)2D3 treatment resulted in reduction in total cell VDR from 100 to 64 fmol/mg protein. Initial Kd estimates with the whole cell binding assay suggested that 1,25-(OH)2D3 treatment resulted in a reduction in VDR Kd from 0.6 to 6.2 nM. This apparent reduction in the affinity of VDR for 1,25-(OH)2D3 was due to degradation of free 1,25-(OH)2[3H]D3 which occurred during whole cell saturation assay. Competitive inhibitors of 1,25-(OH)2D3 metabolism were found to reverse the apparent receptor down-regulation observed in whole cell binding assays of treated cells. In addition, the presence of competitive inhibitors amplified responses of cells to 1,25-(OH)2[3H]D3 treatment as measured by an increased occupancy of VDR by 1,25-(OH)2[3H]D3 and increased up-regulation of VDR over that observed without metabolism inhibitors. These data demonstrate that self-induced target tissue deactivation of 1,25-(OH)2D3 regulates 1,25-(OH)2D3 occupancy of VDR and ultimately the biopotency of 1,25-(OH)2D3 in target cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550427

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  1,25(OH)2D3 receptor regulation and 1,25(OH)2D3 effects in primary cultures of growth cartilage cells of the rat.

Authors:  G Klaus; J Merke; H Eing; U Hügel; P Milde; H Reichel; E Ritz; O Mehls
Journal:  Calcif Tissue Int       Date:  1991-11       Impact factor: 4.333

2.  Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. A new characteristic of genetic hypercalciuric stone-forming rats.

Authors:  J Yao; P Kathpalia; D A Bushinsky; M J Favus
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

3.  Targeted delivery of vitamin D to the colon using β-glucuronides of vitamin D: therapeutic effects in a murine model of inflammatory bowel disease.

Authors:  Jesse P Goff; Nicholas J Koszewski; Joseph S Haynes; Ronald L Horst
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-11-23       Impact factor: 4.052

4.  Serum calcium and vitamin D regulate 1,25-dihydroxyvitamin D3 receptor concentration in rat kidney in vivo.

Authors:  M E Sandgren; H F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption.

Authors:  X Q Li; V Tembe; G M Horwitz; D A Bushinsky; M J Favus
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

6.  Vitamin D metabolism: new concepts and clinical implications.

Authors:  P H Anderson; B K May; H A Morris
Journal:  Clin Biochem Rev       Date:  2003

7.  The vitamin D receptor and the etiology of RANTES/CCL-expressive fatty-degenerative osteolysis of the jawbone: an interface between osteoimmunology and bone metabolism.

Authors:  Johann Lechner; Jürgen Aschoff; Tatjana Rudi
Journal:  Int J Gen Med       Date:  2018-04-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.